<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899378</url>
  </required_header>
  <id_info>
    <org_study_id>SPO109949</org_study_id>
    <nct_id>NCT01899378</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Probiotics in Bangladeshi Infants</brief_title>
  <official_title>Safety and Efficacy of Probiotics in Bangladeshi Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Here the investigators propose to preliminarily investigate the safety and effects of
      probiotics in infants in Bangladesh through a pilot randomized clinical trial. The
      investigators hypothesize that two probiotics are safe for infants in Bangladesh and may have
      an effect on biomarkers of gut health and immunity. The specific aims of this pilot are: i)
      to confirm the safety of administering probiotic strains to infants in low-income countries,
      ii) to determine the effects of dosing frequency on colonization and persistence of
      probiotics in the GI tract, iii) to measure markers of intestinal and immune function and
      microbiota structure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of probiotic in the stool</measure>
    <time_frame>weeks 0-12</time_frame>
    <description>presence of absence of each probiotic in the stool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>duration of study - through study completion</time_frame>
    <description>Any adverse or allergic reactions after probiotic administration, hospitalizations, GI and respiratory symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantity of probiotic in the stool</measure>
    <time_frame>weeks 0-12</time_frame>
    <description>amount of each probiotic present in the stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composition of microbiota</measure>
    <time_frame>weeks 0-12</time_frame>
    <description>microbial community composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical effects</measure>
    <time_frame>daily for 7 days after first probiotic administration, then weeks 2-12</time_frame>
    <description>fever, diarrhea, wheezing, rash, stool frequency, feeding frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut function</measure>
    <time_frame>months 0, 1, 2, 3</time_frame>
    <description>lactulose/mannitol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut inflammation</measure>
    <time_frame>months 0,1,2,3</time_frame>
    <description>fecal neopterin, alpha-1 antitrypsin, and myeloperoxidase - correlated with future growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut inflammation/translocation</measure>
    <time_frame>months 0, 1, 2, 3</time_frame>
    <description>IL22, CD-14, total IgG and c-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>growth</measure>
    <time_frame>month 0, 1, 2, 3</time_frame>
    <description>weight, length, head circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breastfeeding rates</measure>
    <time_frame>month 0, 1, 2, 3</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>10^8 CFU</description>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <other_name>BioGaia Protectis Baby</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum infantis</intervention_name>
    <description>10^9 CFU</description>
    <arm_group_label>daily probiotic</arm_group_label>
    <arm_group_label>weekly probiotic</arm_group_label>
    <arm_group_label>bi-weekly probiotic</arm_group_label>
    <other_name>Align</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants.

          -  Infants 1 -3 months of age at the beginning of the study.

          -  Parents/guardians of each subject are able to understand study procedures and agree to
             participate in the study by giving consent.

          -  Parents and child are planning to remain in Dhaka for the next four months.

        Exclusion Criteria:

          -  Infants with known birth defects.

          -  Infants who have been hospitalized.

          -  Infants who have an acute infection or illness at the time of enrolment.

          -  Infants who are currently taking antibiotics

          -  Infants &lt;1 month of age or &gt;3 months of age.

          -  Infants three standard deviations below mean on anthropometric measures (will be
             referred for medical care).

          -  Infants who are already receiving a probiotic product or treatment.

          -  A diagnosis or suspicion of immunodeficiency disorder.

          -  A diagnosis or suspicion of bleeding disorder that would contraindicate venipuncture.

          -  Family residence outside of Dhaka or families expecting to move outside of Dhaka in
             the next 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yana Emmy E Hoy-Schulz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Parsonnet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Luby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leanne Unicomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Diarrheal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaniz Jannat, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>International Center for Diarrheal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Center for Diarrheal Disease Research, Bangladesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Julie Parsonnet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

